Economic and Medical Evaluation of Health Care Technologies

1. Front Matter

   Pages I-XXVI

   PDF

2. Overview

   1. Front Matter

      Pages 1-1

      PDF

   2. Evaluation and Medicine

      • K. L. White

      Pages 3-15

   3. Medical Evaluation of Health Care Technologies

      • D. J. Balaban, N. I. Goldfarb

      Pages 16-31

   4. Discussion of Paper by Balaban and Goldfarb

      • U. E. Reinhardt

      Pages 32-37

   5. The Role of Economics in the Evaluation of Health Care Technologies

      • A. Williams

      Pages 38-68

   6. Discussion of Paper by Williams

      • J. F. Lacronique

      Pages 69-71

   7. Renal Replacement Therapy, Computerized Axial Tomography, and Cimetidine in Peptic Ulcer Disease

      • D. Taylor

      Pages 72-90

3. Dialysis

   1. Front Matter

      Pages 91-91

      PDF

   2. A Review of the Clinical Evaluation of Dialysis

      • A. Colombi

      Pages 93-104

   3. Discussion of Paper by Colombi

      • J. D. Pole

      Pages 105-108

   4. Economic Evaluation of Dialysis

      • K.-M. Pedersen

      Pages 109-131

   5. Discussion of Paper by Pedersen

      • W. van Eimeren

      Pages 132-134

   6. The Epidemiological Evaluation of Active Therapy of Patients with Renal Failure

      • E. Schmitt, H. Klinkmann

      Pages 135-146

   7. Discussion of Paper by Schmitt and Klinkmann

      • G. Stoddart

      Pages 147-151

   8. Macroeconomic Evaluation of Kidney Dialysis

      • F. F. H. Rutten

      Pages 152-164

   9. Discussion of Paper by Rutten

      • J. Bergström

      Pages 165-168

4. Cimetidine

   1. Front Matter

      Pages 169-169

      PDF

   2. Clinical Evaluation of Cimetidine with Special Reference to Socioeconomic Effects

      • A. Walan

      Pages 171-180

   3. Discussion of Paper by Walan

      • M. F. Drummond

      Pages 181-187

All too frequently, the largest effective barrier to interdisciplinary communication is jargon. The symposium whose proceedings appear in the following pages sought, of course, to eliminate unnecessary and obscurantist jargon; but it sought also to do something far more ambitious - to confront the intellectual issues that are attached to the use of the word "evaluation" in medicine and health services. To this end a carefully selected group of experts in medicine, epidemiology, and health econom­ ics was invited to present papers. They were selected for their reputations either as conceptualizers or as empirical evaluators, or - the rarest breed of expert - as both. The context was to be empirical. Three procedures were selected that had been subject to evaluation but that posed rather different types of problem. The first was the treatment of renal failure by dialysis of various kinds. This has a relatively long history of evaluation, with a large literature, and particularly raises broad policy is­ sues within the health services of Western societies as to - the size of programmes to be provided; the type, location, and mix of treatments; the selection of patients to receive treatment; and the measurement of the success of various strategies. The second was the treatment of duodenal ulcer by a new species of drug - the hista­ mine Hrreceptor antagonists (specifically, cimetidine).

• Cimetidin
• Dialyse
• Evaluierung
• Hirnerkrankung
• Schichtaufnahmeverfahren
• computed tomography (CT)
• dialysis
• drug
• evaluation
• health
• health care
• health services
• medicine
• patients
• tomography

• Department of Economics and Related Studies, University of York, Heslington, York, England

  Anthony J. Culyer

• Interdisziplinäres Forschungszentrum für die Gesundheit St. Gallen, St. Gallen, Switzerland

  Bruno Horisberger

Policies and ethics